Extract:
Based on this comprehensive report published by Gravitas Market Insights, the Active Pharmaceutical Ingredient CDMO market is said to witness a significant growth during the forecast years between 2021 and 2028. Contract manufacturing is a type of outsourcing in which a company contracts with another company to produce its parts, products, or components. The previous manufacturer incorporates these into its own product manufacturing process. The research gives a detailed look at the current CMO market, with a breakdown of each segment by region.
Report Scope in detail:
This latest report edition of Active Pharmaceutical Ingredient CDMO market has been added to our huge database of detailed reports and this envisions to shape the future of all the related businesses. Our team of learned research analysts have studied in-depth and curated the report based on several aspects which include the overview of the market, driving forces, growth rate, market trends, market size, opportunities and challenges of the market; along with detailed competitive analysis on the regional as well as global level. The Active Pharmaceutical Ingredient CDMO market research report renders a thorough analysis of the market on a global aspect and aims on several market segmentation. This report also provides deeper perception into the latest trends of the market and pinpoints crucial product developments of the industry. Furthermore, the report collects numerous factors that have accredited to the growth of the market in the recent years.
Market Dynamics:
• Contract manufacturing is a type of outsourcing in which a company contracts with another company to produce its parts, products, or components.
• The previous manufacturer incorporates these into its own product manufacturing process. The research gives a detailed look at the current CMO market, with a breakdown of each segment by region.
• A contract manufacturing organisation (CMO) is a company that provides entire services to the pharmaceutical sector, from medication discovery to manufacture.
• Pharmaceutical clients can extend their technical resources by outsourcing to a CMO without incurring additional costs.
Active Pharmaceutical Ingredient CDMO Market Segmentation:
By Product
• Highly Potent Active Pharmaceutical Ingredient (HP-API)
• Traditional Active Pharmaceutical Ingredient (Traditional API)
• Antibody Drug Conjugate (ADC)
• Others
By Synthesis
• Biotech
• Synthetic
By Drug
• Generics
• Innovative
By Application
• Oncology
• Hormonal
• Glaucoma
• Cardiovascular
• Diabetes
• Others
Regional Coverage
• North America
o United States
o Canada
o Mexico
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Russia
o Rest of Europe
• Asia Pacific
o China
o India
o Japan
o Korea
o Australia
o Southeast Asia
o Rest of Asia-Pacific
• South America
o Brazil
o Argentina
o Colombia
o Rest of South America
• Middle East & Africa
o GCC
o South Africa
o Rest of Middle East & Africa
Competitive Analysis:
Eminent market players have been outlined in order to extract improved insights into the worldwide businesses. Our research reports offer all-inclusive information on various top most manufacturers that are operational across global regions. We provide company profiles which include detailed overview of the company, business information, business performance, crucial strategies implemented through the years.
Few of the Key Players Covered in Our Report:
• ThermoFisher Pantheon
• Boehringer Ingelheim
• Cambrex
• Piramal Pharma Solutions
• Corden Pharma.
• ReciPharm
• Lonza
• Siegfried
• Samsung Biologics
• Catalent
Impact of COVID19:
The COVID19 pandemic crippled the global economy, it resulted in a worldwide lockdown and this has majorly impacted numerous industries. Our industry experts are working round-the-clock to identify, accumulate and in-time deliver market analysis due to the effect of unprecedented decisions in COVID-19 repercussions on many businesses. The full version of this report will comprise the overall impact of the pandemic, and predicted alteration on the future outlook of the industry, by taking into the account the economic, political, technological and social parameters.
Section 1: Executive Summary
1.1. Active Pharmaceutical Ingredient CDMO Market Industry 360° outline, Year 2016 - 2028
1.2. Business Model Trends
1.3. Growth Trends
1.4. End-User/Synthesis Trends
1.5. Regional Trends
Section 2: Market Dynamics - Active Pharmaceutical Ingredient CDMO Market Industry Insights
2.1. Growth Drivers
2.2. Opportunities
2.3. Industry challenges
2.4. SWOT Analysis
2.5. Porter's Analysis
2.6. Worldwide Industry Landscape, Year 2016 - 2028
2.7. Industry Segmentation
2.8. Technology & Invention landscape
2.9. Regional Landscape
2.9.1. North America
2.9.2. Europe
2.9.3. Asia-Pacific
2.9.4. South America
2.9.5. Middle East & Africa
2.10. Competitive Environment
Section 3: Global Active Pharmaceutical Ingredient CDMO Market, By Product
3.1. Segmentation Analysis, By Product, 2016-2028
3.2. Market Share Segmentation Analysis, By Product, 2016-2028
3.3. Highly Potent Active Pharmaceutical Ingredient (HP-API)
3.3.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
3.4. Traditional Active Pharmaceutical Ingredient (Traditional API)
3.4.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
3.5. Antibody Drug Conjugate (ADC)
3.5.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
3.6. Others
3.6.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
Section 4: Global Active Pharmaceutical Ingredient CDMO Market, By Synthesis
4.1. Segmentation Analysis, By Synthesis, 2016-2028
4.2. Market Share Segmentation Analysis, By Synthesis, 2016-2028
4.3. Biotech
4.3.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
4.4. Synthetic
4.4.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
Section 5: Global Active Pharmaceutical Ingredient CDMO Market, By Drug
5.1. Segmentation Analysis, By Drug, 2016-2028
5.2. Market Share Segmentation Analysis, By Drug, 2016-2028
5.3. Generics
5.3.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
5.4. Innovative
5.4.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
Section 6: Global Active Pharmaceutical Ingredient CDMO Market, By Application
6.1. Segmentation Analysis, By Application, 2016-2028
6.2. Market Share Segmentation Analysis, By Application, 2016-2028
6.3. Oncology
6.3.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
6.4. Hormonal
6.4.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
6.5. Glaucoma
6.5.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
6.6. Cardiovascular
6.6.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
6.7. Diabetes
6.7.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
6.8. Others
6.8.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
Section 7: Global Active Pharmaceutical Ingredient CDMO Market, Regional Analysis
7.1. Global Active Pharmaceutical Ingredient CDMO Market, Regional Analysis
7.2. North America, Country level Analysis
7.2.1. North America Active Pharmaceutical Ingredient CDMO Market estimates and forecast with Growth rate analysis, By Product, 2016 - 2028
7.2.2. North America Active Pharmaceutical Ingredient CDMO Market estimates and forecast with Growth rate analysis, By Synthesis, 2016 - 2028
7.2.3. North America Active Pharmaceutical Ingredient CDMO Market estimates and forecast with Growth rate analysis, By Drug, 2016 - 2028
7.2.4. North America Active Pharmaceutical Ingredient CDMO Market estimates and forecast with Growth rate analysis, By Application, 2016 - 2028
7.2.5. United States
7.2.5.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
7.2.6. Canada
7.2.6.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
7.2.7. Mexico
7.2.7.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
7.3. Europe Country level Analysis
7.3.1. Europe Active Pharmaceutical Ingredient CDMO Market estimates and forecast with Growth rate analysis, By Product, 2016 - 2028
7.3.2. Europe Active Pharmaceutical Ingredient CDMO Market estimates and forecast with Growth rate analysis, By Synthesis, 2016 - 2028
7.3.3. Europe Active Pharmaceutical Ingredient CDMO Market estimates and forecast with Growth rate analysis, By Drug, 2016 - 2028
7.3.4. Europe Active Pharmaceutical Ingredient CDMO Market estimates and forecast with Growth rate analysis, By Application, 2016 - 2028
7.3.5. UK
7.3.5.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
7.3.6. Germany
7.3.6.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
7.3.7. France
7.3.7.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
7.3.8. Italy
7.3.8.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
7.3.9. Spain
7.3.9.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
7.3.10. Russia
7.3.10.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
7.3.11. Rest of Europe
7.3.11.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
7.4. Asia-Pacific Country level Analysis
7.4.1. Asia-Pacific Active Pharmaceutical Ingredient CDMO Market estimates and forecast with Growth rate analysis, By Product, 2016 - 2028
7.4.2. Asia-Pacific Active Pharmaceutical Ingredient CDMO Market estimates and forecast with Growth rate analysis, By Synthesis, 2016 - 2028
7.4.3. Asia-Pacific Active Pharmaceutical Ingredient CDMO Market estimates and forecast with Growth rate analysis, By Drug, 2016 - 2028
7.4.4. Asia-Pacific Active Pharmaceutical Ingredient CDMO Market estimates and forecast with Growth rate analysis, By Application, 2016 - 2028
7.4.5. China
7.4.5.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
7.4.6. India
7.4.6.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
7.4.7. Japan
7.4.7.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
7.4.8. Korea
7.4.8.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
7.4.9. Australia
7.4.9.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
7.4.10. Southeast Asia
7.4.10.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
7.4.11. Rest of Asia-Pacific
7.4.11.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
7.5. South America Country level Analysis
7.5.1. South America Active Pharmaceutical Ingredient CDMO Market estimates and forecast with Growth rate analysis, By Product, 2016 - 2028
7.5.2. South America Active Pharmaceutical Ingredient CDMO Market estimates and forecast with Growth rate analysis, By Synthesis, 2016 - 2028
7.5.3. South America Active Pharmaceutical Ingredient CDMO Market estimates and forecast with Growth rate analysis, By Drug, 2016 - 2028
7.5.4. South America Active Pharmaceutical Ingredient CDMO Market estimates and forecast with Growth rate analysis, By Application, 2016 - 2028
7.5.5. Brazil
7.5.5.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
7.5.6. Argentina
7.5.6.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
7.5.7. Colombia
7.5.7.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
7.5.8. Rest of South America
7.5.8.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
7.6. Middle East & Africa Country level Analysis
7.6.1. MEA Active Pharmaceutical Ingredient CDMO Market estimates and forecast with Growth rate analysis, By Product, 2016 - 2028
7.6.2. MEA Active Pharmaceutical Ingredient CDMO Market estimates and forecast with Growth rate analysis, By Synthesis, 2016 - 2028
7.6.3. MEA Active Pharmaceutical Ingredient CDMO Market estimates and forecast with Growth rate analysis, By Drug, 2016 - 2028
7.6.4. MEA Active Pharmaceutical Ingredient CDMO Market estimates and forecast with Growth rate analysis, By Application, 2016 - 2028
7.6.5. GCC
7.6.5.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
7.6.6. South Africa
7.6.6.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
7.6.7. Rest of Middle East & Africa
7.6.7.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
Section 8: Company Profile - Active Pharmaceutical Ingredient CDMO Market
8.1. ThermoFisher Pantheon
8.1.1. Business Overview
8.1.2. Product & Service Offering
8.1.3. Overall Revenue
8.1.4. Strategic Outlook
8.2. Boehringer Ingelheim
8.2.1. Business Overview
8.2.2. Product & Service Offering
8.2.3. Overall Revenue
8.2.4. Strategic Outlook
8.3. Cambrex
8.3.1. Business Overview
8.3.2. Product & Service Offering
8.3.3. Overall Revenue
8.3.4. Strategic Outlook
8.4. Piramal Pharma Solutions
8.4.1. Business Overview
8.4.2. Product & Service Offering
8.4.3. Overall Revenue
8.4.4. Strategic Outlook
8.5. Corden Pharma.
8.5.1. Business Overview
8.5.2. Product & Service Offering
8.5.3. Overall Revenue
8.5.4. Strategic Outlook
8.6. ReciPharm
8.6.1. Business Overview
8.6.2. Product & Service Offering
8.6.3. Overall Revenue
8.6.4. Strategic Outlook
8.7. Lonza
8.7.1. Business Overview
8.7.2. Product & Service Offering
8.7.3. Overall Revenue
8.7.4. Strategic Outlook
8.8. Siegfried
8.8.1. Business Overview
8.8.2. Product & Service Offering
8.8.3. Overall Revenue
8.8.4. Strategic Outlook
8.9. Samsung Biologics
8.9.1. Business Overview
8.9.2. Product & Service Offering
8.9.3. Overall Revenue
8.9.4. Strategic Outlook
8.10. Catalent
8.10.1. Business Overview
8.10.2. Product & Service Offering
8.10.3. Overall Revenue
8.10.4. Strategic Outlook
*Market size and forecast will be provided from 2016-2028, and forecast period would be 2021-2028
*Details on financial performance and strategic moves and developments may not be captured for unlisted companies
*List of companies profiled in this TOC is tentative and may change after detailed analysis
Request Sample 
Request Discount 
Inquire Before Buy
